ATE147102T1 - Nützliche retrovirale vektoren für die gentherapie - Google Patents

Nützliche retrovirale vektoren für die gentherapie

Info

Publication number
ATE147102T1
ATE147102T1 AT92904720T AT92904720T ATE147102T1 AT E147102 T1 ATE147102 T1 AT E147102T1 AT 92904720 T AT92904720 T AT 92904720T AT 92904720 T AT92904720 T AT 92904720T AT E147102 T1 ATE147102 T1 AT E147102T1
Authority
AT
Austria
Prior art keywords
retroviral vectors
gene therapy
genes
interest
disclosed
Prior art date
Application number
AT92904720T
Other languages
English (en)
Inventor
Lori F Rafield
Lawrence K Cohen
Allan D Callow
Louis K Birinyi
James M Wilson
Richard C Mulligan
Original Assignee
Somatix Therapy Corp
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24431473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE147102(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Somatix Therapy Corp, Whitehead Biomedical Inst filed Critical Somatix Therapy Corp
Application granted granted Critical
Publication of ATE147102T1 publication Critical patent/ATE147102T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/18—Use of ingredients of undetermined constitution or reaction products thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
AT92904720T 1990-10-31 1991-10-31 Nützliche retrovirale vektoren für die gentherapie ATE147102T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60725290A 1990-10-31 1990-10-31

Publications (1)

Publication Number Publication Date
ATE147102T1 true ATE147102T1 (de) 1997-01-15

Family

ID=24431473

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92900015T ATE163046T1 (de) 1990-10-31 1991-10-31 Genetische veränderung von endothelzellen
AT92904720T ATE147102T1 (de) 1990-10-31 1991-10-31 Nützliche retrovirale vektoren für die gentherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92900015T ATE163046T1 (de) 1990-10-31 1991-10-31 Genetische veränderung von endothelzellen

Country Status (10)

Country Link
EP (2) EP0556345B2 (de)
JP (3) JP3249516B2 (de)
AT (2) ATE163046T1 (de)
AU (2) AU659824B2 (de)
CA (2) CA2095153C (de)
DE (2) DE69128893T2 (de)
DK (2) DK0568537T3 (de)
ES (2) ES2115662T3 (de)
GR (1) GR3022909T3 (de)
WO (2) WO1992007573A1 (de)

Families Citing this family (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6544771B1 (en) 1987-12-11 2003-04-08 Cell Genesys, Inc. Retroviral gene therapy vectors and therapeutic methods based thereon
WO1993000103A1 (en) * 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
EP1216710B1 (de) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulierung der systemischen Immunantworten mittels Zytokinen und Antigenen
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
WO1994000133A1 (en) * 1992-06-19 1994-01-06 The General Hospital Corporation Use of mullerian inhibiting substance for treating tumors and for modulating class 1 major histocompatibility antigen expression
US5911983A (en) * 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
GB9222931D0 (en) * 1992-11-02 1992-12-16 Sandoz Ltd Organic compounds
US5830461A (en) * 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
US5658565A (en) * 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
JPH08511507A (ja) * 1993-03-08 1996-12-03 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 哺乳動物宿主の結合組織を処置するための遺伝子導入
FR2704236B1 (fr) * 1993-04-21 1995-06-23 Pasteur Institut Vecteur rétroviral pour la préparation de cellules recombinantes susceptibles d'être implantées in vivo dans un but thérapeutique.
DE69431295T2 (de) 1993-04-21 2003-05-15 Institut Pasteur, Paris Biokompatibles implantat zur in vivo expression und sekretion von therapeutischer verbindung
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
AU1513495A (en) * 1993-12-14 1995-07-03 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
DE4411402A1 (de) * 1994-03-31 1995-10-05 Juergen Schrader DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
WO1995030763A2 (en) * 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
CA2197427A1 (en) * 1994-08-26 1996-03-07 Christopher Wrighton Gene therapy for transplantation and inflammatory or thrombotic conditions
FR2726005B1 (fr) * 1994-10-10 1997-01-03 Adim Lignees immortalisees de cellules endotheliales cerebrales et leurs applications au traitement de differents troubles ou maladies primaires et secondaires neurologiques ou psychiatriques
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU6410596A (en) * 1995-07-31 1997-02-26 Centre De Recherche De L'hopital Sainte-Justine Cytidine deaminase cdna as a positive selectable marker for ene transfer, gene therapy and protein synthesis
FR2737731B1 (fr) 1995-08-07 1997-10-10 Pasteur Institut Sequence de retroelements naturels ou synthetiques ayant pour fonction de permettre l'insertion de sequences nucleotidiques dans une cellule eucaryote
AU1073797A (en) * 1995-11-14 1997-06-05 Somatix Therapy Corporation Joint expression of gtp cyclohydrolase and tyrosine hydroxylase
US5837464A (en) * 1996-01-29 1998-11-17 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
EP0886650A1 (de) * 1996-02-14 1998-12-30 Novartis AG Gentherapie von Endothelzellen mit anti-apoptotischen Proteinen zur Bekämpfung von Zuständen, welche mit Entzündungen und Transplantationen einhergehen.
US5965126A (en) * 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
AUPN970196A0 (en) * 1996-05-06 1996-05-30 Unisearch Limited A long-term and high expression, single gene retroviral vector with applications to progenitor and mature haematopoietic cells
US6027721A (en) * 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
US5885829A (en) * 1996-05-28 1999-03-23 The Regents Of The University Of Michigan Engineering oral tissues
WO1997048806A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
AU4401297A (en) 1996-09-21 1998-04-14 Viromedica Pacific Limited Improved retroviral vectors for gene therapy
US5833651A (en) * 1996-11-08 1998-11-10 Medtronic, Inc. Therapeutic intraluminal stents
US8075880B2 (en) 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
WO1998042854A1 (en) * 1997-03-27 1998-10-01 The Board Of Trustees Of The Leland Stanford Junior University Functional genomic screen for rna regulatory sequences and interacting molecules
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
AU750803B2 (en) 1997-10-29 2002-07-25 University Of Pittsburgh Use of vectors such as adenoviruses and/or adeno associated viruses and/or retroviruses and/or herpes simplex viruses and/or liposomes and/or plasmids as a vehicle for genetic information enabling mammal cells to produce agents for the treatment of bone pathologies
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
US6743631B1 (en) 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy
US6841537B1 (en) 1998-04-22 2005-01-11 Protiva Biotherapeutics Inc. Combination therapy using nucleic acids and conventional drugs
US6841538B1 (en) 1998-04-22 2005-01-11 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and radio therapy
DE19822115B4 (de) * 1998-05-08 2004-04-08 Heinrich-Pette-Institut Retrovirale Gentransfervektoren
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
AU3998799A (en) * 1998-05-20 1999-12-06 Genentech Inc. Treatment for hemophilia
AU4207899A (en) * 1998-05-26 1999-12-13 University Of Florida Lentiviral vector compositions and methods of use
JP2003523166A (ja) 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2002538167A (ja) 1999-03-03 2002-11-12 バイオジェン インコーポレイテッド 脂質の代謝および貯蔵を調節する方法
WO2000053743A1 (en) 1999-03-12 2000-09-14 Gpc Biotech, Inc. Methods and reagents for identifying synthetic genetic elements
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
JP2003518942A (ja) 1999-12-30 2003-06-17 プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 肝細胞成長、形質細胞分化、又はｔ細胞サブセットの活性を、ｘｂｐ−１活性の変調により変調することに関する方法及び組成物
AU2001231009A1 (en) 2000-01-21 2001-07-31 Beth Israel Deaconess Medical Center Use of pro-apoptotic factors in treatment of atherosclerosis
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
WO2001090342A2 (en) 2000-05-22 2001-11-29 Johns Hopkins University Genetic engineering of vascular grafts to resist disease
CA2432542A1 (en) 2000-12-22 2002-07-04 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
EP2345720A3 (de) 2001-07-12 2012-01-25 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
EP1900815B1 (de) 2001-07-12 2016-09-07 University of Massachusetts In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de) 2002-01-25 2006-06-07 Gamida Cell Ltd Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
EP2561887B8 (de) 2003-01-14 2016-12-21 Dana-Farber Cancer Institute, Inc. Sensibilisator für Krebstherapie
EP1624936B1 (de) 2003-05-16 2009-10-28 Universite Laval Cns chlorid-modulierung und verwendung derselben
ES2357116T5 (es) 2003-06-02 2021-09-03 Univ Massachusetts Métodos y composiciones para mejorar la eficacia y especificad de FNAi
DK1633767T3 (en) 2003-06-02 2019-03-25 Univ Massachusetts METHODS AND COMPOSITIONS FOR MANAGING THE EFFECT OF RNA SILENCING
EP1677735B1 (de) 2003-10-17 2014-07-23 Joslin Diabetes Center, Inc. Verfahren und zusammensetzungen zur modulierung der adipozyten-funktion
AU2005222902B2 (en) 2004-03-12 2010-06-10 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
EP2946666B1 (de) * 2004-04-30 2017-11-15 OrbusNeich Medical, Inc. Medizinische vorrichtung mit beschichtung zur erfassung von genetisch veränderten zellen und anwendungsverfahren dafür
EP2453024B1 (de) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
EP2529619B1 (de) 2005-02-17 2015-09-23 Biogen MA Inc. Behandlung neurologischer Störungen
US8889844B2 (en) 2005-08-16 2014-11-18 Takara Bio Inc. Nucleic acid for treatment or prevention of immunodeficiency virus infection
US7485448B2 (en) 2005-09-13 2009-02-03 Takara Bio Inc. Serum-free medium for producing retroviruses
EP1942948A4 (de) 2005-11-04 2010-03-03 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur hemmung der expression des nav1.8-genes
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
CA2629299C (en) 2005-11-12 2017-08-22 The Board Of Trustees Of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
EP3023497A1 (de) 2005-11-18 2016-05-25 Glenmark Pharmaceuticals S.A. Anti-alpha2-integrin-antikörper und deren verwendungen
CA2524619A1 (en) 2005-11-22 2007-05-22 Ottawa Health Research Institute Novel stem cells, nucleotide sequences and proteins therefrom
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US7718629B2 (en) 2006-03-31 2010-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
WO2007127919A2 (en) 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
ES2874149T3 (es) 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
EP2392583A1 (de) 2006-05-19 2011-12-07 Alnylam Europe AG. RNAi-Modulation von AHA und therapeutische Verwendungen davon
EP2584051B1 (de) 2006-05-22 2014-07-16 Alnylam Pharmaceuticals Inc. Zusammensetzungen und Verfahren zur Hemmung von IKK-B-Genexpressionen
MX2008014793A (es) 2006-05-25 2008-12-02 Biogen Idec Inc Metodos para tratar la apoplejia.
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US8664364B2 (en) 2007-01-24 2014-03-04 Carnegie Mellon University Optical biosensors
KR20140102327A (ko) 2007-02-06 2014-08-21 유태준 유전자 요법을 사용한 신경퇴행성 질환의 치료 및 예방
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
KR101252065B1 (ko) 2007-04-20 2013-04-12 다카라 바이오 가부시키가이샤 유전자 치료를 위한 벡터
ES2428009T3 (es) 2007-07-05 2013-11-05 Novartis Ag ARNds para tratar infecciones virales
EP2848688A1 (de) 2007-12-10 2015-03-18 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
JP5697027B2 (ja) 2008-02-15 2015-04-08 タフツ ユニバーシティー マウス網膜上への細胞膜傷害複合体（ｍａｃ）生成のヒト化モデル、並びに、黄斑変性の処置のための組成物とキットと方法
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
SG188121A1 (en) 2008-03-05 2013-03-28 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of eg5 and vegf genes
CN102083969A (zh) 2008-05-06 2011-06-01 乔斯林糖尿病中心股份有限公司 诱导褐色脂肪形成的方法和组合物
EP3208337A1 (de) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Zusammensetzungen zur kombinationshemmung der expression eines mutanten egfr und il-6
CA2739170A1 (en) 2008-09-25 2010-04-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
EA036772B1 (ru) 2008-10-20 2020-12-18 Элнилэм Фармасьютикалз, Инк. Композиции и способы для ингибирования экспрессии транстиретина
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
EP2373382B1 (de) 2008-12-10 2017-02-15 Alnylam Pharmaceuticals, Inc. Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
JP2009148273A (ja) * 2009-01-21 2009-07-09 Ichikazu Nakao 内皮細胞を分化増殖させる方法
WO2010099019A1 (en) 2009-02-24 2010-09-02 Alexion Pharmaceuticals, Inc. Antibodies containing therapeutic tpo/epo mimetic peptides
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
CN102405280B (zh) 2009-03-20 2015-03-04 中胚层公司 重新设定的多能干细胞的制备
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
WO2011024791A1 (ja) 2009-08-25 2011-03-03 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
EP3561077B1 (de) 2009-10-21 2022-12-21 Les Laboratoires Servier Verfahren für zellproliferationsbedingte erkrankungen
WO2011088163A1 (en) 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
EP3329924B1 (de) 2010-03-29 2021-05-05 Alnylam Pharmaceuticals, Inc. Dsrna-therapie für durch transthyretin (ttr) vermittelte augenamyloidose
EP2824111B1 (de) 2010-04-30 2017-03-22 Alexion Pharmaceuticals, Inc. Anti-C5A-Antikörper und Anwendungsverfahren dafür
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
US9102943B2 (en) 2010-10-05 2015-08-11 Takara Bio Inc. Method for producing virus vector
WO2012051301A1 (en) 2010-10-12 2012-04-19 President And Fellows Of Harvard College Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
US8815942B2 (en) 2010-10-20 2014-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
CA2823194A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
CN103649103A (zh) 2011-06-21 2014-03-19 阿尔尼拉姆医药品有限公司 用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
WO2012177949A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
WO2013040517A2 (en) 2011-09-15 2013-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center IMMUNOTHERAPY AND DIAGNOSIS OF MUCORMYCOSIS USING CotH
HK1202581A1 (en) 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
US9399780B2 (en) 2012-03-22 2016-07-26 Takara Bio Inc. Method for producing viral vector
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
EP2851086A1 (de) 2013-09-20 2015-03-25 Sanofi Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
EP2769732A1 (de) 2013-02-22 2014-08-27 Sanofi Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
KR102127358B1 (ko) 2013-03-13 2020-06-29 지니위브 바이오사이언시스, 인코포레이티드 비-복제 형질도입 입자 및 형질도입 입자-기반 리포터 시스템
WO2014197599A1 (en) 2013-06-04 2014-12-11 The Johns Hopkins University Peg-prom mediated surface expression of avidin/streptavidin
EP3003022B1 (de) 2013-06-04 2017-11-22 Virginia Commonwealth University Verwendung eines trunkierten ccn1-promotors für krebsdiagnostik, therapeutika und theranostika
US9951114B2 (en) 2013-06-04 2018-04-24 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
US10166300B2 (en) 2013-06-04 2019-01-01 Virginia Commonwealth University Tripartite cancer theranostic nucleic acid constructs
EP3004872B1 (de) 2013-06-04 2017-10-18 Virginia Commonwealth University Mda-9/syntenin-promotor zur abbildung und behandlung metastatischer krebszellen
DK3049521T3 (en) 2013-09-25 2019-04-23 Univ Cornell Compounds for inducing antitumor immunity and methods thereof
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
PT3191139T (pt) 2014-07-24 2020-11-05 Massachusetts Eye & Ear Infirmary Terapia do gene rpgr para retinite pigmentosa
EP3892291A1 (de) 2014-08-28 2021-10-13 Tufts University Zusammensetzungen, verfahren und kits zur behandlung komplementär hervorgerufener erkrankungen
CA2973878A1 (en) 2015-01-22 2016-07-28 University Of Massachusetts Cancer immunotherapy
CN107428818A (zh) 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
PL3265568T3 (pl) 2015-03-06 2020-11-30 Massachusetts Eye & Ear Infirmary Terapie augmentacji genów w przypadku wrodzonego zwyrodnienia siatkówki spowodowanego mutacjami genu prpf31
EP3735982A1 (de) 2015-03-10 2020-11-11 The University of Massachusetts Abzielung auf gdf6 und bmp-signalisierung für antimelanomtherapie
EP3736287A1 (de) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmunantikörper zur verwendung in der hemmung des krebszellenwachstums
EP3294332A4 (de) 2015-05-14 2018-12-26 Joslin Diabetes Center, Inc. Retinolbindendes protein 3 (rbp3) als schutzfaktor bei nicht diabetischer netzhautdegeneration
US9920100B2 (en) 2015-06-05 2018-03-20 The Chinese University Of Hong Kong Mimotopes of tropomyosin for use in immunotherapy for shellfish and/or arthropod allergy
WO2017066796A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
WO2017066712A2 (en) 2015-10-16 2017-04-20 The Children's Medical Center Corporation Modulators of telomere disease
AU2016355178B9 (en) 2015-11-19 2019-05-30 Massachusetts Institute Of Technology Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
EP3397282A4 (de) 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. Verfahren im zusammenhang mit biologika
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
EP3299460A1 (de) 2016-09-26 2018-03-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Neuartige verbindungen und verfahren zur modulation der ubiquitinierung
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
EP3609577B1 (de) 2017-04-14 2024-09-11 University of Massachusetts Braune fettselektive adipokine
CN110832072B (zh) 2017-04-21 2023-11-07 真基因太科公司 用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
SG11201912240QA (en) 2017-06-28 2020-01-30 Regeneron Pharma Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
SI3658184T1 (sl) 2017-07-27 2024-01-31 Alexion Pharmaceuticals, Inc., Formulacije z visoko koncentracijo protiteles proti-C5
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
US11008602B2 (en) 2017-12-20 2021-05-18 Roche Molecular Systems, Inc. Non-replicative transduction particles and transduction particle-based reporter systems
ES2992014T3 (es) 2018-02-12 2024-12-05 Tufts College CD59 para inhibir la activación del inflamasoma
WO2019200013A1 (en) 2018-04-11 2019-10-17 Cancer Targeting Systems, Inc. Therapeutic constructs for treating cancer
US12582702B2 (en) 2018-05-11 2026-03-24 University Of Massachusetts Methods for improving leptin sensitivity for the treatment of obesity and diabetes
US12404320B2 (en) 2018-05-31 2025-09-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients
SG11202011815SA (en) 2018-06-01 2020-12-30 Sanofi Sa Combination therapy for treating hepatitis b virus infection
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
MD4324851T2 (ro) 2018-07-19 2025-12-31 Regeneron Pharma Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
CA3109804A1 (en) 2018-08-16 2020-02-20 The Regents Of The University Of California Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
AU2019336148B2 (en) 2018-09-06 2025-08-14 Momenta Pharmaceuticals, Inc. Methods of continuous cell culture
KR102933479B1 (ko) 2018-10-23 2026-03-04 리제너론 파아마슈티컬스, 인크. Ny-eso-1 t 세포 수용체 및 이의 사용 방법
CN112996561A (zh) 2018-10-30 2021-06-18 亚力兄制药公司 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
US11325978B2 (en) 2018-11-06 2022-05-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for treating beta-globinopathies
WO2020120649A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
WO2020136154A1 (en) 2018-12-27 2020-07-02 F. Hoffmann-La Roche Ag Non-replicative transduction particles and transduction particle-based reporter systems for detection of acinetobacter baumannii
WO2020142275A1 (en) 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
US11572595B2 (en) 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
MX2022000896A (es) 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
EP4021934A4 (de) 2019-08-30 2024-02-14 The Regents of the University of California Screening-methoden von genfragment-überexpressionen und ihre verwendungen
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
CN114867493B (zh) 2019-10-04 2026-04-10 阿尔伯特爱因斯坦医学院 Kir3dl3是免疫系统的抑制性受体及其用途
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
BR112022010425A2 (pt) 2019-12-03 2022-08-23 Evotec Int Gmbh Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
KR20220109436A (ko) 2019-12-03 2022-08-04 에보텍 인터내셔널 게엠베하 인터페론-결합된 항원 결합 단백질 및 이의 용도
BR112022012093A2 (pt) 2019-12-20 2022-08-30 Momenta Pharmaceuticals Inc Anticorpos contra integrina alfa 11 beta 1
US20220356537A1 (en) 2019-12-31 2022-11-10 Roche Molecular Systems, Inc. Quantitative pcr screening of inducible prophage from bacterial isolates
EP4084819A1 (de) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Lokal verabreichtes tnap zum fördern der periodontalen gesundheit
IL294988A (en) 2020-01-24 2022-09-01 Regeneron Pharma Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
CN115427568A (zh) 2020-02-12 2022-12-02 麻省眼耳科医院 Rp1相关视网膜变性的基于单倍型的治疗
IL297538A (en) 2020-04-24 2022-12-01 Millennium Pharm Inc Anti-cd19 antibodies and uses thereof
AU2021266706A1 (en) 2020-05-05 2022-12-15 Regeneron Pharmaceuticals, Inc. Car comprising CD28 zeta and CD3 zeta
CN116615443A (zh) 2020-09-14 2023-08-18 Vor生物制药股份有限公司 针对cd33的单结构域抗体
AU2021400221A1 (en) 2020-12-18 2023-07-13 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
JP7829595B2 (ja) 2021-04-09 2026-03-13 武田薬品工業株式会社 補体因子ｄを標的とする抗体及びその使用
PE20241789A1 (es) 2021-04-26 2024-09-06 Millennium Pharm Inc Anticuerpos anti-clec12a y usos de los mismos
IL307940A (en) 2021-04-26 2023-12-01 Millennium Pharm Inc Anti-ADGRE2 antibodies and their uses
CA3217914A1 (en) 2021-05-04 2022-11-10 Kevin BRAY Chimeric antigen receptors with mage-a4 specificity and uses thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
IL308337A (en) 2021-05-13 2024-01-01 Us Health Preparations and methods for the treatment of sickle cell disease
WO2022258720A1 (en) 2021-06-09 2022-12-15 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
WO2023064255A2 (en) 2021-10-15 2023-04-20 The Regents Of The University Of California Diagnosis and treatment of anti-pf4 induced thrombocytopenia
KR20240099161A (ko) 2021-10-20 2024-06-28 다케다 야쿠힌 고교 가부시키가이샤 Bcma를 표적화하는 조성물 및 이의 사용 방법
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023089564A1 (en) 2021-11-19 2023-05-25 Janssen Biotech, Inc. Method of treating geographic atrophy with a gene therapy vector expressing soluble cd59
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
EP4507794A1 (de) 2022-04-11 2025-02-19 Vor Biopharma Inc. Bindemittel und verfahren zur verwendung davon
WO2023200897A1 (en) 2022-04-13 2023-10-19 The Regents Of The University Of California Use of viral il-6 in cancer therapy
JP2025515486A (ja) 2022-04-29 2025-05-15 ピュリノミア バイオテック， インコーポレイテッド 好酸球駆動性疾患及び障害を治療するための方法及び組成物
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
KR20250151441A (ko) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
WO2024238565A1 (en) 2023-05-15 2024-11-21 Vor Biopharma Inc. Egf-like module containing mucin-like hormone-like 2 (erm2) binding agents and methods of use thereof
CN121335919A (zh) 2023-05-25 2026-01-13 瑞泽恩制药公司 结合呈递的hpv16、mart1、cmv、ebv或流感肽的t细胞受体
WO2025074268A1 (en) 2023-10-02 2025-04-10 Janssen Biotech, Inc. Methods for treating macular degeneration
WO2025255030A1 (en) 2024-06-03 2025-12-11 Cornell University Interferon gamma responsive chimeric t cell costimulatory receptor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4963481A (en) * 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
WO1989005345A1 (en) * 1987-12-11 1989-06-15 Whitehead Institute For Biomedical Research Genetic modification of endothelial cells
JP2917998B2 (ja) * 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
CA1339354C (en) * 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
JPH04507041A (ja) * 1988-12-13 1992-12-10 アメリカ合衆国 遺伝工学により修飾された内皮細胞およびその利用方法

Also Published As

Publication number Publication date
EP0568537B1 (de) 1998-02-04
JPH07503121A (ja) 1995-04-06
WO1992007943A1 (en) 1992-05-14
DE69123981T3 (de) 2006-06-14
AU659824B2 (en) 1995-06-01
EP0556345A4 (en) 1993-10-06
JPH06503968A (ja) 1994-05-12
EP0556345A1 (de) 1993-08-25
EP0556345B2 (de) 2005-10-12
DE69123981T2 (de) 1997-06-05
WO1992007573A1 (en) 1992-05-14
EP0568537A4 (de) 1993-08-20
DE69128893D1 (de) 1998-03-12
DE69123981D1 (de) 1997-02-13
CA2095153A1 (en) 1992-05-01
AU1266692A (en) 1992-05-26
DK0556345T3 (da) 1997-06-16
CA2095153C (en) 2007-01-09
DK0568537T3 (da) 1998-09-23
EP0556345B1 (de) 1997-01-02
ATE163046T1 (de) 1998-02-15
JP3249516B2 (ja) 2002-01-21
JP2001299367A (ja) 2001-10-30
AU656544B2 (en) 1995-02-09
ES2096750T3 (es) 1997-03-16
AU9017591A (en) 1992-05-26
CA2095256A1 (en) 1992-05-01
ES2115662T3 (es) 1998-07-01
JP3418982B2 (ja) 2003-06-23
GR3022909T3 (en) 1997-06-30
DE69128893T2 (de) 1998-09-10
EP0568537A1 (de) 1993-11-10

Similar Documents

Publication Publication Date Title
DE69123981D1 (de) Nützliche retrovirale vektoren für die gentherapie
GR3025596T3 (en) Compositions and methods for identifying biologically active molecules.
NO20002788D0 (no) Nye forbindelser
AU2836995A (en) Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
IL117425A0 (en) Receptor activation by gas6
ZA969489B (en) Novel transfection agents and their pharmaceutical applications
FR2731014B1 (fr) Molecules d'adn, preparation et utilisation en therapie genique
ATE312190T1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
EP0088195A3 (de) Messenger-RNS dessen Herstellung und Verwendung
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
KR970700771A (ko) 비-바이러스 벡터(Non-viral vector)
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
NZ307444A (en) Polyphenol oxidase genes from lettuce and banana
ATE113294T1 (de) Polycyclische aromatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.
EP0744408A3 (de) Das ob Protein der Rhesusaffen und seine DNA
IL58103A (en) Sila-substituted 1,4-dihydropyridine derivatives,their production and pharmaceutical compositions containing them
FI850814A7 (fi) Proteiineja, farmaseuttisia seoksia, geenejä, vektoreita, isäntäorgan ismeja ja menetelmiä niiden tuottamiseksi.
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE3861271D1 (de) Basisch substituierte benzofurancarbonsaeureamide, verfahren zu ihrer herstellung und sie enthaltende therapeutische mittel.
GB2141430B (en) Peptides, pharmaceutical compositions, genes, vectors, host organisms, processes for their production and diagnostic reagents
ZA844989B (en) Proteins,pharmaceutical compositions,genes,vectors,host organisms and processes for their production
ATE55411T1 (de) Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
UA25443A (uk) Спосіб визhачеhhя життєздатhості тоhкої кишки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee